Back to Rheumatology

OUR EXPERTISE AND SERVICES AVAILABLE IN

Lupus

Overview

Spherix’s coverage of the systemic lupus erythematosus market focuses on rheumatologists’ understanding, diagnosis, and treatment of the disease. Learnings include brand use, factors in brand selection and criteria for evaluating success.

Services Available

Trending market evolution

  • Lupus Nephritis (US)

Exploring the patient journey

  • Lupus Nephritis (US)

  • Moderate to Severe Systemic Lupus Erythematosus (US)

  • Moderate to Severe Systemic Lupus Erythematosus (EU)

Prepping for the pipeline

  • Systemic Lupus Erythematosus (US)

  • Systemic Lupus Erythematosus (EU)

Benchmarking new brand performance

  • Benlysta (GSK) and Lupkynis (Aurinia) in Lupus Nephritis (US)

  • Gazyva (Genentech/Roche) in Lupus Nephritis (US)*

  • Olumiant (Eli Lilly) in Systemic Lupus Erythematosus (US)*

  • Saphnelo (AstraZeneca) in Systemic Lupus Erythematosus (US)*

*Pending approvals and launch

gauging impact of disruptive events

  • Multi Specialty Impact of COVID 19 Rheumatology (US)

  • PCP Treatment of Rheumatology (US)

  • Pediatric Rheumatology (US)

  • Rheumatology Biosimilars Today and Tomorrow (US)

  • The Impact of Biosimilar Usage in Rheumatology (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Lupus Coverage